Bullish case
$79 to $87
More likely if adjusted EPS grows near the top of guidance, Marlboro pricing offsets volume declines, on! and NJOY gain profitable share, and the stock holds above the resistance zone with healthy volume.
Altria Group, Inc. research snapshot
MO AI stock analysis currently reads Altria Group, Inc. as a mature U.S. nicotine company with strong pricing power, high cash generation, dividend support, and persistent volume, regulation, and product-transition risk. The analysis uses scenario ranges, not a certain price prediction. At the July 8, 2026 data cutoff, the latest verified close used here was $72.96 on July 7, 2026, with an implied market capitalization of about $121.84 billion. This is informational research and not investment advice.
Current price
$72.96
Market cap
$121.84 billion
AI score
62 / 100
Rating
High cash yield, regulatory decline risk
Trend status
Uptrend above key moving averages
Data cutoff (updated weekly)
July 8, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Altria sells cigarettes, oral tobacco, nicotine pouches, cigars, and e-vapor products to adult U.S. consumers, with Marlboro still anchoring cash flow. | Medium-high |
| Moat | Moat comes from Marlboro brand power, retail distribution, regulation that raises barriers, pricing power, and scale in U.S. tobacco. | Medium-high |
| Management | Sal Mancuso became CEO in 2026 after serving as CFO, so management should be judged by smoke-free execution, capital allocation, leverage discipline, and dividend coverage. | Medium |
| Financial trend | 2025 revenue declined to $23.279 billion while net income was $6.947 billion; Q1 2026 revenue net of excise taxes grew 5.3%. | High |
| Valuation | The stock trades as a cash-return and dividend compounder, with verified PE near 17.7x and FCF yield near 7.5% at the cutoff price. | Medium-high |
| Technical trend | MO closed above the 50-day and 200-day moving averages, but volume was below its 50-day average, so breakout confirmation matters. | Medium |
| Risk level | The thesis can fail if cigarette volumes fall faster than pricing, FDA rules restrict key products, NJOY or on! disappoint, or litigation and tax pressure rise. | High |
| AI confidence | High for historical financials, market-cap math, and risk mapping. Lower for forward share-price outcomes. | High data confidence |
| Investment certainty | Medium-low certainty because durable cash flow is balanced against structural volume decline and regulatory tail risk. | Medium-low |
MO AI stock forecast
The MO AI stock forecast uses three-year scenario ranges around the $72.96 cutoff close. The financial-rigor model produced a bullish value near $83.40, a base value near $65.60, and a bearish value near $41.40 using EPS growth and terminal PE assumptions. These are scenario outputs, not promises.
$79 to $87
More likely if adjusted EPS grows near the top of guidance, Marlboro pricing offsets volume declines, on! and NJOY gain profitable share, and the stock holds above the resistance zone with healthy volume.
$62 to $70
More likely if Altria keeps cash flow stable but investors apply a lower multiple because cigarette volumes decline and smoke-free growth remains gradual.
$39 to $46
More likely if earnings contract, regulation or litigation damages pricing power, the smoke-free portfolio fails to scale, or the stock loses both the 50-day and 200-day moving averages.
MO AI technical analysis
MO AI technical analysis uses the July 7, 2026 close of $72.96 and public technical snapshots available at the July 8, 2026 data cutoff. The setup was positive but not risk free: price was above the 50-day and 200-day moving averages, while volume was below the 50-day average.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $72.96 | Latest verified close used for this page, dated July 7, 2026. |
| Near support | $71.00 to $71.02 | Centered on the 50-day moving average area reported by Barchart and ChartMill. |
| Deeper support | $64.88 | Approximate 200-day moving average reported by Barchart and ChartMill. |
| Near resistance | $74.56 to $78.00 | The lower end is the recent 52-week high cited by MarketWatch; the upper end is a planning zone for a confirmed breakout. |
| 50-day moving average | About $71.01 to $71.02 | Public technical snapshots showed MO above a rising 50-day average at the cutoff. |
| 200-day moving average | About $64.88 | Public technical snapshots showed MO above a rising 200-day average at the cutoff. |
| Momentum | Positive but extended | ChartMill reported RSI near 62.31, a neutral reading, while moving average signals remained positive. |
| Volume | 5.2 million vs 9.0 million average | MarketWatch reported July 7 volume below the 50-day average, so a breakout needs stronger confirmation. |
| Volatility | Moderate defensive equity volatility | Dividend yield can reduce perceived volatility, but regulatory headlines can create sharp gaps. |
| Invalidation | Close below $71.00, then $64.88 | A close below the 50-day average weakens the short-term setup; losing the 200-day average would challenge the longer trend. |
MO AI trading strategy
The MO AI trading strategy is a rules-based research framework. It is not personalized advice. Traders should pair the setup with live price data, dividend dates, earnings releases, FDA headlines, position sizing, and predefined invalidation levels.
Wait for MO to hold above the $71.00 support area and break the $74.56 resistance area with volume above the recent average.
A failed breakout or close below the 50-day moving average invalidates the short-term setup.
If MO pulls back toward the 50-day average without a negative filing, litigation, or FDA event, compare the yield, payout coverage, and volume trend before considering a reversion trade.
Do not average down if the pullback is caused by an earnings miss, regulatory change, or faster combustible volume decline.
Track Marlboro retail share, cigarette shipment decline, pricing, on! pouch share, NJOY economics, adjusted EPS guidance, debt, dividend coverage, and repurchase pace.
Reduce confidence when cash returns depend more on multiple expansion than on stable earnings and free cash flow.
Investment research summary
Altria monetizes adult nicotine demand through a dominant U.S. cigarette franchise, oral tobacco, nicotine pouches, cigars, and e-vapor products.
The moat is strongest in brand, distribution, scale, and regulatory barriers, but it narrows if consumers migrate faster than Altria can build profitable smoke-free platforms.
The failure path is faster cigarette volume decline, tougher FDA or tax policy, litigation shocks, poor smoke-free economics, and capital returns that mask eroding business quality.
The CEO transition to Sal Mancuso makes capital allocation, leverage discipline, dividend coverage, and smoke-free execution the key scorecard.
Nicotine demand is durable, but combustible tobacco is in structural decline. The long-term trend depends on whether Altria can shift profit pools without losing pricing power.
At $72.96, the stock requires stable cash flow, modest EPS growth, and continuing capital returns. The margin of safety is weaker if investors demand a lower PE for regulatory and volume risk.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| MO closing price | $72.96 on July 7, 2026 | Yahoo Finance historical price snapshot | July 8, 2026 |
| Market capitalization | $121.84 billion, verified as $72.96 x 1.67 billion shares | financial_rigor.py market-cap verification | July 8, 2026 |
| 2025 net revenues | $23.279 billion, down 3.1% | Altria FY2025 results and SEC companyfacts | July 8, 2026 |
| 2025 net income | $6.947 billion | SEC companyfacts cross-checked with third-party summaries | July 8, 2026 |
| 2025 cash and long-term debt | $4.474 billion cash and $25.709 billion long-term debt | SEC companyfacts | July 8, 2026 |
| 2025 diluted EPS | $4.12 reported diluted EPS and $5.42 adjusted EPS base | SEC companyfacts and Altria FY2025 results | July 8, 2026 |
| 2026 Q1 update | Q1 2026 net revenues were $5.428 billion and revenue net of excise taxes rose 5.3% | Altria Q1 2026 results | July 8, 2026 |
| 2026 adjusted EPS guidance | $5.56 to $5.72 | Altria Q1 2026 results | July 8, 2026 |
| Technical moving averages | 50-day about $71.01 to $71.02; 200-day about $64.88 | Barchart and ChartMill technical snapshots | July 8, 2026 |
| Volume and 52-week high context | July 7 volume was 5.2 million shares; 52-week high was $74.56 | MarketWatch July 7, 2026 market data story | July 8, 2026 |
| Leadership | Sal Mancuso is Chief Executive Officer | Altria leadership profile and CEO transition release | July 8, 2026 |
This MO AI stock analysis page is an informational tool only. It is not investment advice, a recommendation, or a promise of future returns. Forecast scenarios are based on available data as of July 8, 2026, may be incomplete, and can be wrong if new filings, market prices, FDA actions, litigation, dividend policy, or macro conditions change.